Invivyd Inc. Announces New Clinical Study to Evaluate Monoclonal Antibody Therapy for Long COVID at RECOVER-TLC Workshop

Reuters

09/04

Invivyd Inc. Announces New Clinical Study to Evaluate Monoclonal Antibody Therapy for Long COVID at RECOVER-TLC Workshop

Invivyd, Inc. (Nasdaq: IVVD) has announced that the SPEAR Study Group has put forward a consensus recommendation for a clinical study design aimed at evaluating the effects of monoclonal antibody therapy on Long COVID. This proposed study, which centers on the use of anti-SARS-CoV-2 spike protein monoclonal antibodies, including Invivyd's VYD2311, will be presented at the Second Annual RECOVER-TLC Workshop, scheduled for September 9-10, 2025, in Bethesda, Maryland. The SPEAR Study Group's proposal reflects current evidence on the potential of monoclonal antibodies in treating Long COVID and identifies VYD2311 as a promising candidate. The study design is set to maintain high antiviral antibody titers over an extended period to suppress chronic infection potentially driving Long COVID. Drs. Amy Proal and David Putrino will present the study design for consideration by RECOVER-TLC, with Dr. Putrino scheduled to present the clinical study design on September 10, 2025, at 9:25 a.m. ET, followed by Dr. Proal's discussion on the antiviral landscape at 1:00 p.m. ET on the same day.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9523078-en) on September 04, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2564199376"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564199376\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564199376?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564199376","market":"fut","top_or_hot":-1,"title":"Invivyd Inc. Announces New Clinical Study to Evaluate Monoclonal Antibody Therapy for Long COVID at RECOVER-TLC Workshop","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Invivyd Inc. Announces New Clinical Study to Evaluate Monoclonal Antibody Therapy for Long COVID at RECOVER-TLC Workshop\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVVD\">Invivyd, Inc.</a> (Nasdaq: IVVD) has announced that the SPEAR Study Group has put forward a consensus recommendation for a clinical study design aimed at evaluating the effects of monoclonal antibody therapy on Long COVID. This proposed study, which centers on the use of anti-SARS-CoV-2 spike protein monoclonal antibodies, including Invivyd's VYD2311, will be presented at the Second Annual RECOVER-TLC Workshop, scheduled for September 9-10, 2025, in Bethesda, Maryland. The SPEAR Study Group's proposal reflects current evidence on the potential of monoclonal antibodies in treating Long COVID and identifies VYD2311 as a promising candidate. The study design is set to maintain high antiviral antibody titers over an extended period to suppress chronic infection potentially driving Long COVID. Drs. Amy Proal and David Putrino will present the study design for consideration by RECOVER-TLC, with Dr. Putrino scheduled to present the clinical study design on September 10, 2025, at 9:25 a.m. ET, followed by Dr. Proal's discussion on the antiviral landscape at 1:00 p.m. ET on the same day.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9523078-en) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Invivyd Inc. Announces New Clinical Study to Evaluate Monoclonal Antibody Therapy for Long COVID at RECOVER-TLC Workshop</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvivyd Inc. Announces New Clinical Study to Evaluate Monoclonal Antibody Therapy for Long COVID at RECOVER-TLC Workshop\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-04 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Invivyd Inc. Announces New Clinical Study to Evaluate Monoclonal Antibody Therapy for Long COVID at RECOVER-TLC Workshop\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVVD\">Invivyd, Inc.</a> (Nasdaq: IVVD) has announced that the SPEAR Study Group has put forward a consensus recommendation for a clinical study design aimed at evaluating the effects of monoclonal antibody therapy on Long COVID. This proposed study, which centers on the use of anti-SARS-CoV-2 spike protein monoclonal antibodies, including Invivyd's VYD2311, will be presented at the Second Annual RECOVER-TLC Workshop, scheduled for September 9-10, 2025, in Bethesda, Maryland. The SPEAR Study Group's proposal reflects current evidence on the potential of monoclonal antibodies in treating Long COVID and identifies VYD2311 as a promising candidate. The study design is set to maintain high antiviral antibody titers over an extended period to suppress chronic infection potentially driving Long COVID. Drs. Amy Proal and David Putrino will present the study design for consideration by RECOVER-TLC, with Dr. Putrino scheduled to present the clinical study design on September 10, 2025, at 9:25 a.m. ET, followed by Dr. Proal's discussion on the antiviral landscape at 1:00 p.m. ET on the same day.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9523078-en) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL9HlGVZ:1","article_id":"2564199376","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564199376","pubTimestamp":1756983753,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Invivyd, Inc.  has announced that the SPEAR Study Group has put forward a consensus recommendation for a clinical study design aimed at evaluating the effects of monoclonal antibody therapy on Long COVID. This proposed study, which centers on the use of anti-SARS-CoV-2 spike protein monoclonal antibodies, including Invivyd's VYD2311, will be presented at the Second Annual RECOVER-TLC Workshop, scheduled for September 9-10, 2025, in Bethesda, Maryland. The SPEAR Study Group's proposal reflects current evidence on the potential of monoclonal antibodies in treating Long COVID and identifies VYD2311 as a promising candidate. The study design is set to maintain high antiviral antibody titers over an extended period to suppress chronic infection potentially driving Long COVID. Drs. Amy Proal and David Putrino will present the study design for consideration by RECOVER-TLC, with Dr. Putrino scheduled to present the clinical study design on September 10, 2025, at 9:25 a.m. ET, followed by Dr. P","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IVVD":"Invivyd, Inc.","BK4588":"碎股","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4539":"次新股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Invivyd Inc.在RECOVER-TLC研讨会上宣布评估新冠后遗症病单克隆抗体疗法的新临床研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IVVD":0.9,"NDAQ":0.9},"content_text":"Invivyd Inc. Announces New Clinical Study to Evaluate Monoclonal Antibody Therapy for Long COVID at RECOVER-TLC Workshop\n    \n\nInvivyd, Inc. (Nasdaq: IVVD) has announced that the SPEAR Study Group has put forward a consensus recommendation for a clinical study design aimed at evaluating the effects of monoclonal antibody therapy on Long COVID. This proposed study, which centers on the use of anti-SARS-CoV-2 spike protein monoclonal antibodies, including Invivyd's VYD2311, will be presented at the Second Annual RECOVER-TLC Workshop, scheduled for September 9-10, 2025, in Bethesda, Maryland. The SPEAR Study Group's proposal reflects current evidence on the potential of monoclonal antibodies in treating Long COVID and identifies VYD2311 as a promising candidate. The study design is set to maintain high antiviral antibody titers over an extended period to suppress chronic infection potentially driving Long COVID. Drs. Amy Proal and David Putrino will present the study design for consideration by RECOVER-TLC, with Dr. Putrino scheduled to present the clinical study design on September 10, 2025, at 9:25 a.m. ET, followed by Dr. Proal's discussion on the antiviral landscape at 1:00 p.m. ET on the same day.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9523078-en) on September 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}